Show simple item record

dc.contributor.authorLin, Xiaoyan
dc.contributor.authorXu, Zhili
dc.contributor.authorCarey, Lawrence
dc.contributor.authorRomero, Julián 
dc.contributor.authorMakriyannis, Alexandros
dc.contributor.authorHillard, Cecilia J.
dc.contributor.authorRuggiero, Elizabeth
dc.contributor.authorDockum, Marilyn
dc.contributor.authorHouk, George
dc.contributor.authorMackie, Ken
dc.contributor.authorAlbrecht, Phillip J.
dc.contributor.authorRice, Frank L.
dc.contributor.authorHohmann, Andrea G.
dc.date.accessioned2022-05-19T08:12:31Z
dc.date.available2022-05-19T08:12:31Z
dc.date.issued2022
dc.identifier.issn0304-3959spa
dc.identifier.urihttp://hdl.handle.net/10641/2972
dc.description.abstractCB2 cannabinoid receptors (CB2) are a promising therapeutic target that lacks unwanted side effects of CB1 activation. However, the cell types expressing CB2 that mediate these effects remain poorly understood. We used transgenic mice with CB2 promoter–driven expression of enhanced green fluorescent protein (EGFP) to study cell types that express CB2 and suppress neuropathic nociception in a mouse model of chemotherapy-induced peripheral neuropathy. Structurally distinct CB2 agonists (AM1710 and LY2828360) suppressed paclitaxel-induced mechanical and cold allodynia in CB2EGFP reporter mice with established neuropathy. Antiallodynic effects of AM1710 were blocked by SR144528, a CB2 antagonist with limited CNS penetration. Intraplantar AM1710 administration suppressed paclitaxel-induced neuropathic nociception in CB2EGFP but not CB2 knockout mice, consistent with a local site of antiallodynic action. mRNA expression levels of the anti-inflammatory cytokine interleukin-10 were elevated in the lumbar spinal cord after intraplantar AM1710 injection along with the proinflammatory cytokine tumor necrosis factor alpha and chemokine monocyte chemoattractant protein-1. CB2EGFP, but not wildtype mice, exhibited anti-GFP immunoreactivity in the spleen. However, the anti-GFP signal was below the threshold for detection in the spinal cord and brain of either vehicle-treated or paclitaxel-treated CB2EGFP mice. EGFP fluorescence was coexpressed with CB2 immunolabeling in stratified patterns among epidermal keratinocytes. EGFP fluorescence was also expressed in dendritic cells in the dermis, Langerhans cells in the epidermis, and Merkel cells. Quantification of the EGFP signal revealed that Langerhans cells were dynamically increased in the epidermis after paclitaxel treatment. Our studies implicate CB2 expressed in previously unrecognized populations of skin cells as a potential target for suppressing chemotherapy-induced neuropathic nociception.spa
dc.language.isoengspa
dc.publisherPainspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectCB2 reporter mousespa
dc.subjectChemotherapy-induced peripheral neuropathyspa
dc.subjectCB2 cannabinoid receptorsspa
dc.subjectPeripheral analgesic mechanismsspa
dc.subjectKeratinocytesspa
dc.subjectLangerhans cellsspa
dc.titleA peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy evidence from a CB2 reporter mouse.spa
dc.typejournal articlespa
dc.type.hasVersionAMspa
dc.rights.accessRightsopen accessspa
dc.description.extent1720 KBspa
dc.identifier.doi10.1097/j.pain.0000000000002502spa
dc.relation.publisherversionhttps://journals.lww.com/pain/Fulltext/2022/05000/A_peripheral_CB2_cannabinoid_receptor_mechanism.7.aspxspa


Files in this item

FilesSizeFormatView
3.- A peripheral CB2 cannabinoid ...1.678MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España